Although skeletal effects were not evaluated, many studies were performed in the INA-6 SCID-hu model for the anti-MM activity of the anti-inflammatory drug atiprimod (Neri et al., 2007), the anti-DKK1 monoclonal antibody BHQ880 (Fulciniti et al., 2009), the IκB kinase inhibitor, β-MLN120B (Hideshima et al., 2006), and a telomerase inhibitor (Shammas et al., 2008). This evidence concerns the gene DKK1 and Miyoshi myopathy.